Asbestos & Cancer: An Update. Suresh H. Moolgavkar, M.D., Ph.D.



Similar documents
Update of the scientific evidence on asbestos and cancer. Kurt Straif, MD MPH PhD. The IARC Monographs

Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis

Review of Eliminating occupational cancer in Europe and globally by J. Takala

D.M. Bernstein * WHO review Page 1 of 8

Executive Summary All invited experts at the meeting agreed that:

Lung cancer and asbestos

Scientific Update on Safe Use of Asbestos. Robert P. Nolan, PhD International Environmental Research Foundation New York, New York

Changing Trends in Mesothelioma Incidence. Hans Weill, M.D. Professor of Medicine Emeritus Tulane University Medical Center

ANNEX 2: Assessment of the 7 points agreed by WATCH as meriting attention (cover paper, paragraph 9, bullet points) by Andy Darnton, HSE

EFFECT OF CHILDREN'S AGE AND LIFE EXPECTATION ON MESOTHELIOMA RISK 1

RR876. Mesothelioma mortality in Great Britain. The revised risk and two-stage clonal expansion models

Mathematical Modeling of Risk Acceptability Criteria

Trevor L Ogden BSc. Ph D

Mesothelioma Trends as Predictors of the Asbestos- Related Lung Cancer Burden

The Burden of Occupational Lung Cancer Paul A. Demers, PhD

The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure a comparison of risk models based on asbestos exposed cohorts

Malignant Mesothelioma Among Employees of a Connecticut Factory that Manufactured Friction Materials Using Chrysotile Asbestos

Asbestos, Asbestosis, and Lung Cancer

- Compensation issues

What has changed to justify the US Senate s bill to ban asbestos now?

Uses and Abuses of Pathology in Asbestos-exposed Populations

OCCUPATIONAL LUNG CANCER

Asbestos: health effects and risk. Peter Franklin Senior Scientific Officer, EHD Senior Research Fellow, UWA

Plaintiffs Experts Latest Pathological Theories

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

Worldwide mesothelioma mortality trends

Elimination of Asbestos- Related Diseases WHO action. Dr Ivan D. Ivanov Public Health and Environment WHO Headquarters

How To Determine The Risk Of Mesothelioma In Brake Workers

Current Usage and Health Significance of the Modern Use of Chrysotile Products: Review of Recently Published Evidence

Asbestos-Related Lung Cancer and Malignant Mesothelioma of the Pleura: Selected Current Issues

NISG Asbestos. Caroline Kirton

Sir William Osler: Listen to the patient; the patient tells you everything.

THE TIMES OF OCCURRENCE OF MESOTHELIOMAS IN RATS FOLLOWING INOCULATION WITH ASBESTOS

National Specialty Society for Community Medicine Position Statement on Chrysotile Asbestos. June 2010

Mesothelioma incidence modeling and forecasting

Survey on the Mortality from Malignant Tumors of Female Asbestos Spinning Workers

Pathologist s Discussion of Plaintiffs Latest Theories

An Evaluation of the Risks of Lung Cancer and Mesothelioma from Exposure to Amphibole Cleavage Fragments

The Carcinogenicity of Chrysotile Asbestos A Review

Preparation of a hygienist s legal reports for asbestosinduced. Robin Howie, Robin Howie Associates, Edinburgh

MODELS FOR MESOTHELIOMA INCIDENCE FOLLOWING EXPOSURE TO FIBERS IN TERMS OF TIMING AND DURATION OF EXPOSURE AND THE BIOPERSISTENCE OF THE FIBERS

Chapter 7: Effect Modification

Cancer Risk Factors in Ontario. Dusts and Fibres

Asbestos and Mesothelioma in Ontario

HANDLING LUNG CANCER CLAIMS

Any Exposure Above Bac ound! Is It Really Causative?

Chrysotile and Lung Cancer Yano et al. Cancer Mortality among Workers Exposed to Amphibole-free Chrysotile Asbestos

Emerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden

The British Occupational Hygiene Society Faculty of Occupational Hygiene INTERNATIONAL MODULE SYLLABUS W504 ASBESTOS AND OTHER FIBRES

June 20, : Wagner Testimony on Workplace Exposure to Asbestos. This is an archive page. The links are no longer being updated.

Asbestos related health risks

Asbestos-Related Lung Cancer: How big business lawyers are hurting cancer patients efforts to secure justice. By J. Conard Metcalf

PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON*

How To Prevent Asbestos From Being Released Into The Environment

Asbestos exposure during Canterbury rebuild unlikely to cause significant health problems for house occupants report finds

Asbestos risks, safety and its role in lung disease

Epidemiology of Malignant Mesothelioma An Outline

Mesothelioma among shipyard workers in Monfalcone, Italy

Asbestos Fibre Concentrations in the Lungs of Brake Workers: Another Look

Basic Study Designs in Analytical Epidemiology For Observational Studies

A 37-year observation of mortality in Chinese chrysotile asbestos workers

Health Effects of Asbestos Exposure

Developments in Asbestos Cancer Risk Assessment

Actuarial projections for mesothelioma: an epidemiological perspective Mark Clements, Geoffrey Berry and Jill Shi

Asbestos. General information

An evaluation of the risks of lung cancer and mesothelioma from exposure to amphibole cleavage fragments

Producing Analytical Data, Microscopy and Analytical Procedures

BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA

6. MODELLING THE RELATIONSHIP BETWEEN RISK, DOSE AND TIME

Asbestos and Mesothelioma a briefing document for the Metropolitan Police

An Application of the G-formula to Asbestos and Lung Cancer. Stephen R. Cole. Epidemiology, UNC Chapel Hill. Slides:

Testimony of. Dr. James Crapo. April 26, 2005

Asbestos Review Program Update

ASBESTOS. Know what it is and how you can protect yourself. environmental affairs Department: Environmental Affairs REPUBLIC OF SOUTH AFRICA

A Meta-Analysis of Asbestos-Related Cancer Risk That Addresses Fiber Size and Mineral Type

A Conference on Asbestos & Mesothelioma

O R D E R BY THE COURT: _S/M. FAITH ANGELL M. FAITH ANGELL UNITED STATES MAGISTRATE JUDGE

Presence of asbestos fibres in indoor and outdoor air in the city of Thetford Mines: Estimation of lung cancer and mesothelioma risks

Estimation of the Number of Lung Cancer Cases Attributable to Asbestos Exposure

Transcription:

Asbestos & Cancer: An Update Suresh H. Moolgavkar, M.D., Ph.D.

Fiber Type and Cancer Epidemiological data clearly indicate that not all fiber types have the same potency as carcinogens. With respect to potency: Crocidolite>>Amosite>>Chrysotile

Outline of Talk Review of epidemiological evidence. Role of biopersistence in determining carcinogenic potency. Experimental evidence relating biological halflife to potency. Quantitative relationship between half-life and carcinogenic potency. Implications for asbestos risk.

Review of Epidemiological Evidence Hodson & Darnton, 2000. Berman & Crump, 2005. McDonald et al, 2001.

Hodgson & Darnton, 2000. Careful quantitative analyses based on 17 cohorts occupationally exposed to asbestos. Conclusions: Mesothelioma: Croc:Amosite:Chrysotile::500:100:1 Lung Cancer: Amphiboles:Chrysotile::10-50:1

Berman & Crump, 2005 Careful quantitative analyses of 20 cohorts occupationally exposed to asbestos (14 of 17 in H&D included). Conclusions: Mesothelioma: Amphiboles:Chrysotile::660:1 Lung Cancer: Amphiboles:Chrysotile::3.5:1

McDonald et al, 2001 Case-control study of mesothelioma and lung burden of asbestos. Clear association with amphiboles. Much weaker association with chrysotile. Caveat: Appropriate controls were difficult to obtain.

Central Issues Biopersistence Fiber Dimensions

Risk Assessment Paradigm Time dependent Exposure Dose Response Deposition, Clearance (Biopersistence) Dose-response model

Figure 1 Fiber Burden as Function of Age 250000 Exposure: 100 fibers/ml from day 70 for 728 days Fiber burden 200000 150000 100000 Amosite e-glass 50000 RCF 1a 0 X 607 100 300 500 700 900 Age

Model for analyses Need model that takes explicit account of time-dependent pattern of lung dose, i.e., fiber burden. Not sufficient to consider cumulative or average dose. Empirical statistical models do not have desirable properties. Models based on ideas of multistage carcinogenesis are preferable.

General Multistage Model Three main phases in cancer development: 1. Accumulation of genetic changes leading to partial abrogation of growth control: Initiation. 2. Clonal expansion of initiated cells: Promotion. 3. Acquisition of further genetic changes during clonal expansion leading to one (or more) malignant cells: Malignant Conversion. Consider action of environmental agents (e.g., smoking, exposure to fibers) on each of the phases of the process.

Risk Assessment for Fibers Objective of Analyses: Develop rationale for regulation based on relatively short-term deposition and clearance experiments so that long-term oncogenicity experiments need not be performed. Strategy: Demonstrate that a fiber is a fiber independent of chemistry, i.e., oncogenic potential depends only on temporal pattern of fiber burden and not on fiber type.

Have experimental data on the following types of fibers: RCF1 (controls, 3, 9, 16 and 30 mg./m 3 exposure groups); RCF2, RCF3, RCF4 (each at 30mg./ m 3 exposure); MMVFs 10, 11, 21, 22 (controls, and for each MMVF 3, 16, 30 mg./ m 3 exposures); X607 (30 mg./ m 3 exposure group); Chrysotile (10 mg./ m 3 exposure group). Serial sacrifices performed - information on fiber count in the lungs and on tumor pathology.

RESULTS Data consistent with the hypothesis that a fiber is a fiber.

Range of unit risks is about 2.0 x 10 5-9.0 x 10-5. X607 alone 4.5 x 10-5 NS RCF1 alone 8.8 x 10-5 NS X607 + RCF1 7.0 x 10-5 NS MMVF21 5.3 x 10-5 NS MMVF22 2.1 x 10-5 NS MMVF21+22 5.1 x 10-5 NS MMVF10+11 3.7 X 10-5 NS All MMVF 4.4 x 10-5 S!! All Fibers 6.1 x 10-5 S!!

Extend analyses to other fibers Extend analyses to 12 fibers considered by Bernstein et al (1996). Use their estimated weighted half lives for the long fibers to generate lung burdens under the EU protocol. Use estimated consensus parameter from analyses of RCF and MMVF to generate Unit Risks and tumor probabilities.

Figure 1 Fiber Burden as Function of Age 250000 Exposure: 100 fibers/ml from day 70 for 728 days Fiber burden 200000 150000 100000 Amosite e-glass 50000 RCF 1a 0 X 607 100 300 500 700 900 Age in days

Figure 2 Tumor Probability as a Function of Age 0.20 Exposure: 100 fibers/ml from day 70 for 728 days Amosite 0.15 e-glass Tumor Probability 0.10 0.05 X 607 RCF 1a 0.00 Control 100 300 500 700 900 Age in days

Figure 3 Unit Risk for various fibers 0.0020 Amosite 466.2 Unit Risk 0.0015 0.0010 Fiber L 45.0 e-glass 68.4 RCF1a 41.0 0.0005 MMVF 11 13.0 Fiber H 13.0 X607 Fiber F Fiber A Fiber B 3.5 2.5 Fiber C 4.1 9.8 8.5 Fiber G 5.4 0.0000 1 2 3 4 5 6 7 8 9 10 11 12 Fiber

Figure 4 Unit Risk as a function of WHL 0.0020 0.0020 III III 0.0015 0.0015 II II Unit Risk 0.0010 I Unit Risk 0.0010 I 0.0005 0.0005 0.0000 0.0000 0 20 40 60 0 10 20 30 40 WHL WHL

Figure 2 Excess Risk as a function of exposure 0.3 Amosite 0.2 Excess Risk e-glass RCF1a 0.1 X607 0.0 5 30 55 80 105 130 155 180 Exposure (fibers/ml)

Conclusions 1. Good evidence from limited experimental data that carcinogenic potential of long fibers is determined principally by biopersistence (half-life). 2. The ratio of amphibole/chrysotile half-lives in rodent lungs is consistent with the amphibole/chrysotile ratio in human lung cancer risks as reported in Hodgson & Darnton, but not Berman & Crump. 3. The ratio of amphibole/chrysotile half-lives in rodent lungs under-estimates the amphibole/chrysotile ratio in human mesothelioma risks.